Search Results - "Blommestein, H.M"

P53 REAL‐WORLD TREATMENT SEQUENCES AND COSTS OF 96 PATIENTS WITH MULTIPLE MYELOMA FROM DIAGNOSIS TO DEATH by Seefat, M.R., Cucchi, D.G.J., Groen, K., Donker, M.L., Hem, K.G., Westerman, M., Gerrits, A.M., Beeker, A., Donk, N., Blommestein, H.M., Zweegman, S.

Get full text

P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV) by Seefat, M.R., Stege, C.A.M., Timmers, G.J., Levin, M.D., Hoogendoorn, M., Ypma, P.F., Nijhof, I.S., Velders, G.A., Strobbe, L., Durdu-Rayman, N., Westerman, M., Davidis-van Schoonhoven, M.A., van Kampen, R.J.W., Beeker, A., Koster, A., Dijk, A.C., van de Donk, N.W.C.J., van der Spek, E., Leys, M.B.L., Silbermann, M.H., Groen, K., van der Burg-de Graauw, N.C.H.P., Sinnige, H.A.M., van der Hem, K.G., Levenga, T.H., Bilgin, Y.M., Sonneveld, P., Klein, S.K., Nasserinejad, K., Blommestein, H.M., Cucchi, D.G.J., Lissenberg-Witte, B.I., Zweegman, S.

Get full text

PCN127 Policy Maker, Please Carefully Consider Your Needs: Does Outcomes Research of Bortezomib for Advanced Multiple Myeloma Reduce Uncertainty? by Franken, M.G, Gaultney, J.G, Blommestein, H.M, Huijgens, P.C, Sonneveld, P, Redekop, W.K, Uyl-de Groot, C.A

Get full text

The Importance of Long-Term Surveillance of Stage IB Melanomas: Unexpectedly Low Survival Subsequent to Recurrence by Leeneman, B, Franken, M.G, Blommestein, H.M, van Gils, C.W.M, van der Meijde, E, Wouters, M.W.J.M, Plaisier, P.W, Kruit, W.H.J, van Ruth, S, ten Tije, A.J, Hendriks, M.P, Coupe, V.M.H, Uyl- de Groot, CA

Get full text

Cost-effectiveness of abemaciclib in early breast cancer patients: one size fits all or tailoring to patients’ needs by Jongbloed, L., Blommestein, H.M., van Schoubroeck, H., Martens, J.W.M., Wilting, S.M., Uyl-de Groot, C.A., Jager, A.

Get full text

RW3 The Use of Real-World Evidence in HTA of CLASS III Medical Devices in Europe by Klein, P., de Groot, S., Blommestein, H.M., Pongiglione, B., Torbica, A., Al, M.J.

Get full text

PCN418 ASSESSMENT OF STUDIES EVALUATING INCREMENTAL COSTS, EFFECTIVENESS OR COST-EFFECTIVENESS OF SYSTEMIC THERAPIES IN BREAST CANCER BASED ON CLAIMS DATA: A SYSTEMATIC REVIEW by Luyendijk, M., Vernooij, R.W.M., Blommestein, H.M., Siesling, S., Uyl-de Groot, C.A.

Get full text

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial by Seefat, M.R., Stege, C.A.M., Lissenberg-Witte, B.I., Levin, M.D., Timmers, G.J., Hoogendoorn, M., Ypma, P.F., Klein, S.K., Velders, G.A., Westerman, M., Strobbe, L., Durdu-Rayman, N., Davidis-van Schoonhoven, M.A., van Kampen, R.J.W., Dijk, A.C., Koster, A., Silbermann, M.H., van der Spek, E., Beeker, A., Erjavec, Z., de Graauw, N.C.H.P., Leys, M.B.L., Sonneveld, P., van de Donk, N.W.C.J., Nasserinejad, K., Blommestein, H.M., Cucchi, D.G.J., Zweegman, S.

“…Frailty in newly-diagnosed multiple myeloma (NDMM) patients is associated with treatment-related toxicity, which negatively affects health-related quality of…”
Get full text

PCN29 - The Importance of Long-Term Surveillance of Stage IB Melanomas: Unexpectedly Low Survival Subsequent to Recurrence by Leeneman, B., Franken, M.G., Blommestein, H.M., van Gils, C.W.M., van der Meijde, E., Wouters, M.W.J.M., Plaisier, P.W., Kruit, W.H.J., van Ruth, S., ten Tije, A.J., Hendriks, M.P., Coupe, V.M.H., Uyl- de Groot, CA

Get full text